AbbVie, following in footsteps of Lilly and Takeda, pays Anima $42M to go after undruggable targets
https://www.fiercebiotech.com/biotech/abbvie-following-footsteps-lilly-and-takeda-pays-anima-42m-go-after-undruggable-targets
Medical Innovation Exchange @ Copywrite 2021. All Rights Reserved.